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Examination by laser scanning confocal fluorescence imaging microscopy
of the subcellular localisation of anthracyclines in parent and multidrug
resistant cell lines
H.M. Coley"3, W.B. Amos2, P.R. Twentyman' & P. Workman"4
'MRC Clinical Oncology and Radiotherapeutics Unit and 2Laboratory ofMolecular Biology, Hills Road, Cambridge CB2 2QH,
UK.
Summary This study highlights the usefulness of laser scanning confocal microscopy in the examination of
subcellular disposition of anthracyclines in tumour cell lines. The distribution of anthracycline compounds has
been studied in two pairs of parental and multidrug resistant (MDR) cell lines. For the parental EMT6 mouse
mammary tumour cell line EMT6/P treated with doxorubicin (DOX) the anthracycline fluorescence was shown
to be predominantly nuclear but with some particulate cytoplasmic fluorescence and very low levels of plasma
membrane staining. In the same experiments much fainter fluorescence was seen for the EMT6/AR1.0 MDR
subline which hyperexpresses P-glycoprotein. The loss of nuclear fluorescence was comparatively greater than
loss of cytoplasmic fluorescence. For the human large cell lung cancer line COR-L23/P cellular DOX
disposition was markedly nuclear with nuclear membrane staining and diffuse cytoplasmic fluorescence. For
the MDR line COR-L23/R, which lacks P-glycoprotein expression, DOX fluorescence was reduced in the
nucleus compared with the parental line, but an intense area of perinuclear staining was seen consistent with
localisation to the Golgi apparatus. The morpholinyl-substituted analogue MR-DOX achieved very similar
subcellular distribution in both parental and MDR lines, consistent with its retention of activity in the latter.
The presence of verapamil during anthracycline exposure increased the intensity of fluorescence in the MDR
lines, particularly in the nucleus. Relatively little effect was seen in the parental lines. Confocal microscopy
provides high resolution images of the subcellular distribution of anthracyclines in parent and MDR cell lines.
Differences in drug disposition in various cell lines may provide insights into the mechanism of multidrug
resistance and suggest strategies for its therapeutic circumvention.
Major research efforts have been directed towards elucidating
the mechanisms underlying multidrug resistance (MDR) and
developing strategies for its therapeutic circumvention. In the
case of the latter, various pharmacological approaches have
been suggested based on in vitro data obtained in MDR cell
lines. One such approach is to use structurally-altered anal-
ogues of the natural product compounds (e.g. vinca alka-
loids, anthracyclines, colchicine) associated with this form of
drug resistance. Certain analogues of the anthracycline doxo-
rubicin (DOX) have been shown to exhibit improved activity
in MDR lines over that seen for the parent compound (Hill
et al.,1985; Scott et al., 1986; Coley et al., 1989a; Twentyman
et al., 1986). For example, 9-alkyl substituted anthracyclines
have been identified as being very effective agents against
MDR cells as have analogues in which the amino group of
the daunosamine sugar is incorporated within a morpholinyl
ring (Coley et al., 1990). A mechanism whereby such com-
pounds retain their cytoxicity in MDR cell lines is by
diminishing the drug accumulation defect that is closely
associated with this particular form of drug resistance (Coley
et al., 1989b).
A second strategy involves the use of membrane-active
resistance modifying agents, such as verapamil (VRP) and
cyclosporin A (CYA), which have been shown to enhance the
cellular accumulation of the anthracyclines (Tsuruo et al.,
1984; Coley et al., 1989b). Again the mechanism involves
abolishing MDR-associated defects in drug accumulation.
The most common correlate for reduced drug accumulation
in MDR cells is the presence of a 170 kD membrane protein,
P-glycoprotein (Pgp), which is believed to act as an energy-
dependent drug efflux pump. This action is generally thought
to be inhibited by resistance-modifying agents. Since the
analogues which retain activity in MDR cells appear to evade
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cellular efflux by Pgp, both pharmacological approaches sug-
gested for the circumvention of MDR are believed to have a
close association with Pgp.
Reduced cellular drug accumulation and/or enhanced efflux
is also seen in certain MDR cell lines, usually exhibiting
relatively low degrees of resistance, which nevertheless do not
express Pgp (McGrath & Center, 1988; Coley et al., 1991). In
these cases the involvement of alternative membrane trans-
port proteins has been proposed (McGrath & Center, 1988).
In general, studies on drug accumulation and efflux involve
measurement of the whole cell drug content, which is essen-
tially representative of the averaged drug accumulated per
cell. However, several reports have indicated distinct patterns
of intracellular accumulation and localisation for the
anthracyclines (Dietel & Seidel, 1990; Willingham et al.,
1986; Keizer et al., 1989). Such studies have been facilitated
by the fact that anthracyclines are highly fluorescent
molecules and their presence in cellular material can be
visualised by fluorescence microscopy. For instance, DOX
and daunorubicin (DNR) have been shown to be localised in
the nucleus of many cultured cell lines (Egorin et al., 1974;
Krishan et al., 1976). In contrast AD32, marcellomycin, car-
minomycin and aclacinomycin A appear to be principally
localised within the cytosplasm of tumour cells (Krishan et
al., 1976; Egorin et al., 1979; 1980).
Recent technical developments have resulted in the com-
mercial availability of laser scanning confocal fluorescence
microscopy equipment. Confocal microscopy has several
advantages over conventional fluorescence microscopy, mainly
in terms of its greater resolution and elimination of epifluor-
escence (White et al., 1987). Laser scan microscopy has been
used to study subcellular anthracycline localisation with
much improved resolution over conventional fluorescence
microscopy (Schuurhuis et al., 1989; 1991; Gervasoni et al.,
1991). We have therefore used this technique to study the
subcellular localisation of anthracyclines in selected human
and murine MDR cell lines. The MDR cell lines chosen
included both Pgp-positive and Pgp-negative types and are
those which we have previously characterised for sensitivity
to DOX and structurally modified anthracyclines, resistance
modulation by VRP and CYA, and cellular accumulation
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and efflux properties (Coley et al., 1989b; Coley et al., 1991).
Particular attention has been paid to differences in drug
distribution seen within matched pairs ofwild-type and drug-
resistant cell lines. We have examined both Pgp-expressing
(classical) and non-Pgp-expressing MDR cell lines in an
attempt to clarify the influence of Pgp on subcellular drug
distribution of anthracycline analogues in the absence or
presence of resistance modifiers.
Material and methods
Cell lines and culture conditions
The present study used the murine mammary tumour cell line
EMT6/P and the human large cell lung cancer cell line
COR-L23/P, alongside their MDR sublines EMT6/ARI.0
and CORL23/R, respectively (Twentyman et al., 1990; Reeve
et al., 1990). The EMT6 cell lines were maintained as mono-
layers in Eagles' minimal essential medium with Earles' salts
and with 20% new born calf serum (Gibco Biocult Paisley,
UK) in 75 cm2 flasks with penicillin and streptomycin (at
concentrations of 100 units ml-' and 100lsg'ml' respec-
tively). Stock cultures were grown in an atmosphere of 92%
air, 8% CO2 at 37°C. EMT6/AR1.0 was maintained in 1.0fig
ml-' DOX, with drug removal at least two days before use in
experiments. The COR-L23 cell lines were maintained as
monolayer cultures in RPMI medium (Gibco Biocult) with
10% foetal calf serum (Seralab, Crawley Down, UK). Other
culture conditions were as for the EMT6 cell lines.
In order to obtain single cell suspensions, EMT6 cell line
monolayers were subjected to two rinses with 0.1% trypsin in
phosphate buffered saline (PBS) followed by a 15 min
incubation at 37°C. Cells were then resuspended in complete
Eagle's medium by repeated pipetting and subsequently
counted using a haemocytometer. The COR-L23 cell lines
were subjected to two rinses with trypsin (0.4%) and versene
(0.02%) in PBS and incubated for 15 min. The cells were
then reduced to a single cell suspension and counted as
before.
Drugs
Doxorubicin (DOX) was obtained from Dr Frederico
Spreafico, Farmitalia Carlo Erba, Milan, Italy. Morpholinyl
doxorubicin (MR-DOX) was obtained from Dr E Acton,
MD Anderson Hospital and Tumor Institute, Houston,
Texas, USA. Both drugs were dissolved directly in sterile
distilled water at 500lagml-', filter sterilised (pore size
0.2tsm) and stored in aliquots at - 20°C. The drug solutions
were thawed and diluted in distilled water immediately before
use. Verapamil (VRP) was obtained as a 250fg ml-'
aqueous solution in sealed ampoules (Abbott Laboratories,
Queenborough, UK) and diluted in PBS.
Preparation ofcellsfor confocal microscopy studies
Sterile glass cover slips were placed in sterile tissue culture
Petri dishes. Single cell suspensions of the various cell lines
were prepared at 5 x 104 cells ml-' in the appropriate
medium and volumes of 10 ml were pipetted into each of the
dishes containing the coverslips. All dishes were left over-
night at 37°C in gassing incubators. Following the overnight
incubation, tissue culture dishes were aspirated dry and then
fresh culture medium, containing drug in a volume of 10 ml,
was gently pipetted onto the cell monolayers attached to the
glass cover slips. The drugs were used at the following con-
centrations: DOX I0 Lgml-', MR-DOX 1 Ag ml-' and VRP
3.3 fig ml '. Cells on coverslips were exposed to drug-
containing medium for 2 h. The coverslips were then sub-
jected to two rapid rinses with ice-cold PBS and placed into a
sealed moisture box to prevent drying out prior to micro-
scopic examination. The cover slips with attached cell mono-
layers were inverted with the cell layer face down onto clean
microscope slides, and sealed around the edges with silicon
grease to prevent drying out of the preparation.
Confocalmicroscopy
The instrument used was the MRC 500 confocal microscope,
developed at the MRC Centre, Cambridge (White et al.,
1987), and now manufactured by Biorad Lasersharp Ltd.
This was attached to the phototube of a conventional micro-
scope, in this case the 'Optiphot' inverted microscope
(Nikon, Japan). A 15 mW argon laser (Ion Laser Technology
Inc, Salt Lake City, USA) emitting at 488 nm and 514 m
wavelength was used as the excitation source. The fluor-
escence signal was detected by means ofphotomultipliers and
assembled into an image by using the standard Biorad frame
store. In all experiments described here, the 488 nm laser line
was used for excitation in the Biorad BHS filter block, which
allows detection of emitted light at all wavelengths above
515 nm.
Results
All Figures (except Figure 1) are at identical magnification
and (except for Figure 2c) were obtained using identical
instrument gain settings. Scale bars, where shown, corres-
pond to 25 lsm. Figure 1 is at a 1.3-fold increased magnifi-
cation.
Subcellular localisation ofDOX in EMT6parent and resistant
lines
Figure 1 shows phase-contrast and fluorescence images of a
typical single cell of the EMT6/P mouse mammary tumour
parental cell line after a 2 h exposure to DOX at 10jgml-'.
A lower power field (fluorescence only) is shown in Figure
2a. It can be seen that the DOX fluorescence is localised
predominantly in the nucleus of the EMT6/P line, where the
nuclear envelope is clearly distinguishable and there are dis-
tinct spots of intense fluorescence within the nucleus
presumably involving chromosomal DNA. Small regions of
less intense fluorescence are also seen within the cytoplasm,
consistent with the localisation of drug in vesicles, but the
plasma membrane is barely discernable. In addition, there is
some degree of heterogeneity with regard to the extent of
fluorescence seen within cells of the EMT6/P cell line popula-
tion.
By contrast, in the MDR cell line EMT6/AR1.0 which
hyperexpresses Pgp (Figure 2b and Figure 2c using an in-
creased instrument gain setting), the fluorescence is much less
intense than in EMT6/P (Figure 2a) following DOX
exposure. The major difference between the parent and resis-
tant cells appears to be the level of nuclear fluorescence,
which is very much higher in EMT6/P than in EMT6/AR1.0.
Although nuclear fluorescence is barely discernable in Figure
2b, clear spots of fluorescence are still seen in the cytoplasm.
Relatively speaking, therefore, there is a greater loss of
nuclear than cytoplasmic fluorescence. Interestingly, Figure
2c shows plasma membrane fluorescence in EMT6/AR1.0 in
some cells to a similar level as that for the nuclear envelope.
This is clearly different from the relative membrane
fluorescence in the parent cells (Figure 2a) where the nuclear
membrane is evidently brighter than the plasma membrane.
Effect of VRP on localisation ofDOX in EMT6parent and
resistant lines
Figure 3a shows a moderate increase in DOX fluorescence
for EMT6/P in the presence of VRP, as compared to the
control in Figure 2a, using the same instrument settings.
However, comparison of Figure 2b (EMT6/ARl.0 minus
VRP) and Figure 3b (EMT6/ARI.0 plus VRP, using the
same instrument gain settings), reveals a dramatic VRP-
induced increase in overall fluorescence. This large increase in
nuclear fluorescence was seen in all EMT6/AR1.0 cells. By1318 H.M. COLEY et al.
a
b
Figure 1 a, Phase contrast image of a single EMT6/P cell
incubated with DOX (1Olgmlh) for 2 h b, Fluorescence image
of the same cell.
contrast, the cytoplasmic fluorescence is rather similar in
resistant cells with and without VRP. A large increase in
nuclear/cytoplasmic fluorescence ratio therefore results.
Interestingly, the plasma membrane appears not so distinct in
the VRP-treated MDR cell line as in the same line without
VRP.
Subcellular localisation ofMR-DOX in EMT6parent and
resistant lines
Figure 4a illustrates the subcellular localisation of
fluorescence after a 2 h exposure of EMT6/P cells to
Figure 2 a, EMT6/P cell line incubated with DOX (10ILgml-')
for 2 h b, EMT6/ARI1.0 cell line, conditions as for a. c, EMT6/
ARO. cell line, conditions as for a but with greater instrument
gain to increase image intensity. Scale bar = 25 im.
1 tLg ml-' of MR-DOX (the morpholinyl analogue of DOX)
and Figure 4b shows the equivalent results obtained with the
EMT6/AR1.0 resistant line. This is of interest as MR-DOX
retains a high degree of activity against the MDR line (Coley
et al., 1990). It is clear that the fluorescence pattern for this
analogue is very similar to that for DOX itself in the parental
line. A striking observation, however, is that MR-DOX
shows a much higher staining intensity than does DOX in the
resistant line. In fact the level of staining is essentially equal
to that seen with the parental line. Moreover, the qualitative
staining pattern remains the same.CONFOCAL IMAGING OF ANTHRACYCLINE DISTRIBUTION 1319
Effect of VRP on the localisation ofDOX in COR-L23 parent
and resistant lines
Cells of the VRP-treated COR-L23/P line (Figure 6a) show a
moderate decrease in nuclear fluorescence compared to that
seen in the absence of VRP (Figure 5a). Moreover, some
particulate staining throughout the cytosplasm is discernable,
which is not seen in the absence of VRP. The cytoplasmic
membrane is not well defined. As seen in Figure 6b, VRP has
a greater effect on the COR-L23R MDR subline. The
nuclear fluorescence intensity is markedly increased as is the
diffuse fluorescence in the cytoplasm. The distinct perinuclear
Golgi-like fluorescence is not much changed in intensity and
therefore constitutes a smaller proportion of the overall cel-
lular fluorescence. The plasma membrane is ill-defined. The
staining pattern for COR-L23/R in the presence of VRP is
therefore much closer to that seen for the parental COR-L23/P
line, with an overall increase in nuclear fluorescence.
Subcellular localisation ofMR-DOX in COR-L23 parent and
resistant lines
Figures 7a and 7b show the fluoresence distribution obtained
with MR-DOX in the COR-L23/P and COR-L23/R cell
lines. MR-DOX retains almost complete activity with respect
to the parental line in this subline (Coley et al., 1990). It can
be seen that the analogue behaves very similarly to DOX in
the COR-L23/P parental line. In the resistant line, nuclear
fluorescence is similar to that in the parent cells. However
there is more diffuse cytoplasmic fluorescence and the plasma
membrane is much more clearly defined. In general, nuclear
fluorescence is greatly increased for MR-DOX compared to
DOX and the characteristic perinuclear Golgi-like staining in
the COR-L23/R line is markedly attenuated.
a
Figure 3 a, EMT6/P cell line incubated with DOX (1I0 gmlL)
and VRP (3.3ggml-') for 2h b, EMT6/AR1.0 cell line, condi-
tions as for a. Scale bars = 25gim.
Effect of VRP on the localisation ofMR-DOX in EMT6
parent and resistant lines
Under the same conditions for which VRP produced a
marked increase in fluorescence staining for DOX in EMT6/
ARO. but not EMT6/P cells, the resistance modifier had no
effect on the staining intensity or the qualitative subcellular
disposition of MR-DOX in either EMT6 line (data not
shown).
Subcellular localisation ofDOX in COR-L23 parent and
resistant lines
Figures 5a and 5b show the fluorescence staining patterns
seen following a 2 h exposure to 1Ogigml-' DOX in the
COR-L23/P parental human large cell lung cancer cell line
and the COR L23/R MDR subline which fails to express
membrane Pgp but nevertheless exhibits reduced DOX
accumulation (Coley et al., 1991). In the COR-L23/P
parental line (Figure 5a), the staining pattern for DOX is
quite different from that seen in the corresponding MDR
subline. Nuclear staining is extremely intense and a diffuse,
although less intense, staining is also seen in the cytoplasm.
The plasma membrane is visible in some cells. It can be seen
from Figure 5b that the nuclear staining intensity in COR-
L23/R is markedly reduced, although some particulate
nuclear and cytoplasmic fluorescence is seen and nuclear
membrane staining is also evident. However, a novel site of
DOX-associated fluorescence is revealed in COR-L23/R.
Many cells show a characteristic and highly intense area of
perinuclear staining, with a distribution suggestive of
localisation to the Golgi complex.
h
Figure 4 a, EMT6/P cell line incubated with MR-DOX (1 fig
ml-') for 2 h b, EMT6/AR1.0 cell line, conditions as for a. Scale
bars = 25gim.1320 H.M. COLEY et al.
a COR-L23/P and EMT6/P was that the former showed a
more diffuse staining in the cytoplasm, and drug-containing
cytoplasmic vesicles were not a feature. COR-L23/R showed
an unusual pattern of intensely stained perinuclear clusters of
fluorescence, consistent with a Golgi location.
In a study which used conventional fluorescence micros-
copy in L1210 leukaemia drug-sensitive and DOX-resistant
cell lines it was found that DOX fluorescence was
predominantly localised in the nucleus of the sensitive L1210
line, whereas the L1210 DOX-resistant line was devoid of
nuclear fluorescence and the cytoplasm was the primary loca-
tion for DOX fluorescence (Ross et al., 1986). However, the
Pgp status of the resistant cell line used in this study is not
stated. In addition, a recent report by Gervasoni et al. (1991)
described the subcellular localisation of DNR in a panel of
parental and MDR cell lines. They found that, in the paren-
tal cell lines, fluorescence was predominantly nuclear
whereas, in the resistant cell lines, (both Pgp-positive and
Pgp-negative) fluorescence was distributed into the cytoplasm
b in distinct punctate regions. Our results are largely in agree-
Waf lment with these reports. A number of studies have also
specifically addressed the important question of nuclear to
cytoplasmic ratios of anthracycline disposition (Schuurhuis et
al., 1989; 1991; Keizer et al., 1989). The report by Keizer et
al. (1989) showed that for a panel of Pgp-expressing MDR
lines with levels of resistance varying from 10 to 2000-fold,
an inverse correlation between resistance and accumulation
could be seen and there was a gradual shift from a 'mainly
nuclear' to a 'mainly cytoplasmic' drug distribution. The data
were interpreted as indicating that the same mechanism of
resistance was operating throughout. Quantitative measure-
ment of nuclear/cytoplasmic fluorescence ratio has been
reported by Schuurhuis (1991), and drug distribution changes
a
Figure 5 a, COR-L23/P cell line incubated with DOX (10fig
ml-') for 2 h. (Note mitotic cell in the centre of the field) b,
COR-L23/R cell line, conditions as for a.
Effect of VRP on the localisation ofMR-DOX in COR-L23
parent and resistant lines
Addition of VRP to MR-DOX produced little change in the
fluorescence intensity or qualitative distribution in either
parent or resistant cells (data not shown).
Discussion
Confocal microscopy has many advantages over conventional
fluorescence microscopy, notably a much improved resolu-
tion. As indicated by the present study the subcellular
localisation of the anthracyclines could be clearly visualised
in much greater detail than that described in previous pub-
lications which have used conventional fluorescent micro-
scopy (Egorin et al., 1980; Keizer et al., 1989; Gigli et al.,
1989). In contrast to some other compounds, the anthracy-
clines themselves appeared relatively resistant to photo-
bleaching by the laser.
In the drug sensitive EMT6/P cell line, the most intense
fluorescence was nuclear, particularly in the nuclear mem-
brane and in discrete spots within the nucleus. There was
also a particulate staining and larger areas of fluorescence in
the form of vesicles within the cytoplasm. Very much fainter
fluorescence was seen in the Pgp-hyperexpressing resistant
subline EMT6/AR1.0. Increasing the gain of the instrument
allowed us to see that the overall qualitative pattern of
fluorescence was similar to that in the parent, although there
was relatively more fluorescence in the cytoplasm than in the
nucleus. The subcellular localisation of DOX in the COR-
L23 human lung cancer cell lines was different from that seen
in the EMT6 lines. A major difference between parental lines
b
Figure 6 a, COR-L23/P cell line incubated with DOX (10pg
ml-') plus VRP (3.3jLgml-') for 2 h b, COR-L23/R cell line,
conditions as for a.CONFOCAL IMAGING OF ANTHRACYCLINE DISTRIBUTION 1321
Figure 7 a, COR-L23/P cell line incubated with MR-DOX (1 pg
ml-') for 2 h b, COR-L23/R cell line, conditions as for a. Scale
bars =251lm.
with time have also been quantitated directly using radio-
labelled DNR (Marquardt & Center, 1992). Whilst such a
quantitative approach undoubtedly provides useful inform-
ation, it may also overlook many of the more subtle changes
in drug distribution, such as those depicted in photomicro-
graphs obtained from the present study.
Certain MDR lines may contain a greater number of
stained vacuoles than their drug-sensitive parental counter-
parts, as for example in the COR-L23 cell line pair in the
present study. Zamoro and Beck (1986) found that treatment
of MDR cells with cytotoxic concentrations of vinblastine or
DOX produced an increase in the number of vacuoles. It is
possible that the vacuoles are lysosomes or endosomes that
become enlarged after trapping protonated cationic com-
pounds (De Duve et al., 1974). The presence of such cytop-
lasmic vesicles may indeed provide supportive evidence for an
increase in membrane trafficking in MDR lines. Moreover,
the data reported here may provide indirect evidence in
support of a different method of DOX efflux for the COR-
L23/R cell line, as compared to EMT6/AR1.0. For EMT6/
ARL.0 the Pgp-dependent efflux mechanism may pre-
dominantly take place at the level of the plasma membrane
resulting in a large decrease in fluorescence over all regions
of the cell. As reported previously (Coley et al., 1991) the
defect in DOX accumulation in the COR-L23/R cell line was
not evident until 1 h following drug exposure, in contrast
to the reduced DOX accumulation seen in EMT6/AR1 .0
which was evident at earlier time points (Coley et al.,
1989b).
The observation of intense staining apparently in groups of
granules located in the perinuclear cytoplasm of COR-L23/R
cells may well therefore indicate involvement of an alter-
native membrane trafficking mechanism. This appears to be
based on trapping of drug within the Golgi complex.
Fluorescence distribution given by wheat germ agglutinin
resembles that seen for DOX in COR-L23/R (Barrand et al.,
1993) which supports and reaffirms our observations of
Golgi-staining. The same phenomenon of apparent Golgi
trapping of DNR was described by Willingham et al. (1986)
in both parental and MDR human KB carcinoma cells. An
increase in drug accumulation in the lysosomes and Golgi
elements of drug-resistant cells was observed, using epifluor-
escence photometry. A fluorescence microscopy study by
Hindenburg et al. (1989) also reported a similar finding in
HL-60 DOX-resistant cells, which was equated with
enhanced energy-dependent efflux.
Incorporation of VRP into the drug-incubation stage with
DOX resulted in a noticeable increase in cellular fluorescence
for EMT6/AR1.0, with little change for EMT6/P. There was
evidence of considerable heterogeneity within the EMT6/
ARL.0 line in terms of VRP-induced changes in the subcellu-
lar localisation of DOX. Nuclear fluorescence was noted for
some cells whereas, in other cells, fluorescence was mainly in
large cytoplasmic granules. Hence VRP did not completely
restore the altered subcellular localisation of DOX seen in
EMT6/AR1.0 to that in the parent line for all cells. Our
results are in line with those of Shoji et al. (1991) who used
video microscopy to show that VRP, and to a lesser extent
cyclosporin A, caused increases in cytoplasmic to nuclear
ratios of DOX distribution in a Chinese hamster ovarian
carcinoma MDR line expressing Pgp. A report by Schuurhuis
et al. (1989) demonstrated that, at complete reversal of resis-
tance, the amount of intracellular DOX at the IC50 and the
ratio of nuclear to cytoplasmic DOX fluorescence in an
MDR variant of the A2780 ovarian cancer line were the
same as in the parental line. In contrast to this, the dose of
VRP (3.3ytg ml-') which we have used in the present study is
not completely sufficient to reverse DOX resistance in the
EMT6 cell line pair cell (Coley et al., 1989a). Therefore, it is
not unexpected that we did not see total restoration of the
parental pattern of drug distribution. An interesting study by
Lelong et al. (1991) describes the use of a fluorescently-
tagged VRP derivative, Bodipy-VRP, in Pgp-transfected
NIH3T3 MDR cells, in the presence of VRP itself. The
fluorescent compound was shown to accumulate rapidly into
organelles, notably lysosomes. It may well be, therefore, that
VRP-induced cytoplasmic DOX fluorescence seen in our
study represents a portion of lysosomally-trapped drug, con-
tributing to an overall increase in cellular drug accumulation.
In the COR-L23 cell line pair, the major effect of VRP
added to DOX was again in the resistant subline.
Fluorescence was increased both in the nucleus and generally
throughout the cytoplasm. The fluorescence specifically in the
cytoplasmic vesicles, however, showed little change, sugges-
ting that the capacity of these bodies to accumulate drug
may have been saturated even in the absence of VRP. The
effects of VRP were, however, generally less than those seen
in EMT6/AR1.0 and these results are therefore in line with
our earlier report describing the modest effect of VRP in
modifying DOX resistance in the COR-L23/R cell line.
(Coley et al., 1991).
MR-DOX is an anthracycline analogue in which the amino
group of the daunosamine sugar moiety is incorporated into
a morpholinyl ring. This substitution appears to be pivotal in
its effective cytotoxic action vs MDR lines (Coley et al.,
1990). In contrast to DOX, the subcellular localisation of
MR-DOX was shown to be very similar for both the drug
sensitive and drug resistant EMT6 and COR-L23 cell lines.
The quantitative level of fluorescence was also shown to be
similar for these cell lines, in agreement with our previous
observation that morpholinyl anthracyclines achieve similar
whole cell levels in the same cell lines (unpublished data). In
addition, the morpholinyl anthracyclines appear to be
effluxed at identical rates in parental and MDR cell line pairs
(Coley et al., unpublished data). It can be concluded that, in
contrast to the situation for DOX, the increased expression
of membrane Pgp in the EMT6/AR1.0 cell line had no effect1322 H.M. COLEY et al.
on the subcellular disposition of MR-DOX. Moreover, con-
comitant treatment with VRP appeared to have no obvious
effect on the subcellular localisation of MR-DOX, for either
parent or MDR lines.
A recent report by Lothstein et al. (1992) describes cellular
disposition of a DOX analogue N-benzyladriamycin-14-
valerate, AD 198, in a Pgp-positive murine cell line. Like
MR-DOX, AD 198 showed similar cytotoxic activity in
parental and MDR lines with no significant differential in
cellular accumulation. As seen for MR-DOX with the COR-
L23 cell lines. AD 198 was predominantly localised in the
perinuclear region of the cytoplasm in both the parental and
the MDR line. In addition, VRP failed to change the dis-
tribution of AD 198 into the nucleus, a finding similar for
MR-DOX and VRP in the cell lines used in the present
study.
In conclusion, the high resolution of laser scanning con-
focal fluorescence imaging has been employed to study the
subcellular localisation of anthracyclines with a degree of
clarity not possible with conventional fluorescence micros-
copy. The data reported here both support and extend our
earlier observations using total cellular fluorescence (Coley et
al., 1989b) concerning the correlations between altered
subcellular drug localisation, decrease in intracellular drug
accumulation and Pgp hyperexpression. Distinct differences
in subcellular DOX localisation are seen for parent and
MDR variant lines. However, the structurally modified anth-
racycline MR-DOX exhibits a similar subcellular localisation
for both MDR and parent cell lines, consistent with the
substantial retention of cytotoxic activity of this analogue in
MDR cell lines (Streeter et al., 1985; Coley et al., 1990). The
effects ofVRP could also be demonstrated in terms ofaltera-
tions in subcellular drug disposition. Most importantly, the
different patterns of drug distribution seen between different
cell types and different agents lend support to the view that
drug accumulation in MDR is a highly complex process, and
one which is intimately involved in the resistant phenotype.
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